Marksans Pharma Limited (NSE: MARKSANS) reported financial results for Q2 and H1 FY27, marking a significant milestone with quarterly revenue crossing ₹900 crore for the first time. The company’s Q2FY27 EBITDA surged 48% to a record ₹214 crore, while H1FY27 PAT nearly doubled to ₹303 crore. Mark Saldanha, Founder, Chairman & Managing Director, highlighted the company’s strong performance, driven by broad-based growth across all regions.

Q2FY27 Highlights

In Q2FY27, Marksans Pharma’s operating revenue reached ₹940 crore, up 30.5% year-on-year (YoY). Adjusted for acquisition impact, revenue growth remained robust at 25%. EBITDA grew 48.3% to ₹214 crore, with margins expanding by 274 basis points to 22.8%. Notably, the UK & Europe market grew 64.9% to a record ₹405 crore, while the US & North America segment delivered its highest-ever quarter at ₹421 crore.

H1FY27 Performance

For H1FY27, revenue grew 32.9% to ₹1,781 crore. EBITDA rose 74.7% with margins up 574 basis points to 24.0%, and PAT nearly doubled to ₹303 crore. The company’s operating cash flow reached ₹322 crore, 4.3 times the previous year, and cash balances closed at ₹1,124 crore. Marksans Pharma’s trailing twelve-month return on capital employed (ROCE) improved to 24.7%.

Mark Saldanha emphasized the company’s expanding global footprint, robust product pipeline, and strong net-cash position. ‘We enter the next phase of our growth journey from a position of considerable strength,’ he said. ‘Our focus remains on sustaining profitable organic growth while selectively pursuing strategic acquisitions that strengthen our capabilities and market presence. We remain confident in our growth trajectory and committed to creating sustainable long-term shareholder value.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Marksans Pharma Limited

Marksans Pharma Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Marksans gains 16.4% over three months and trades near its 52-week highs. The business compounds revenue at 16.7% and profits at 16.2% CAGR. That is strong double-digit growth on both counts. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock gives back 1.7% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 16.7% and profits at 16.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Marksans Pharma Limited.

Kopran Limited (NSE: KOPRAN) has released its quarterly investor presentation for Q2 FY 2026-27, showcasing significant financial and operational highlights. The company, a global pharmaceutical powerhouse, reported robust revenue growth and operational performance across its API and Formulation segments.

Financial Highlights

The company’s revenue from operations for Q2 FY 2026-27 stood at Rs. 21,126 lakhs, marking a substantial increase from Rs. 15,399 lakhs in the same period last year. The EBITDA for the quarter was Rs. 1,822 lakhs, reflecting a healthy margin of 8.62%. Despite a forex loss of Rs. 219 lakhs, the net profit for the quarter was Rs. 439 lakhs, indicating a strong financial performance.

Operational Performance

Kopran Limited’s API segment continued to drive growth, with the company’s Atenolol and Carbapenem products leading the charge. The Formulations segment also performed well, with significant contributions from Anti-Diabetic and Anti-Hypertensive products. The company’s state-of-the-art manufacturing facilities in Maharashtra and Gujarat ensured high compliance with global regulatory standards.

Looking Ahead

Kopran Limited remains committed to driving sustainable growth through strategic imperatives such as capacity expansion, regulatory compliance, and cost optimization. The company’s focus on R&D and capacity enhancement positions it well for future growth and sustainability in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.

Sai Parenterals Limited (NSE: SAIPARENT) has announced its un-audited financial results for the quarter and half-year ended 30th September 2026, showcasing significant growth and strategic advancements. Revenue from operations stood at Rs. 196.1 crore, up 9.0% quarter-over-quarter (QoQ) from Rs. 179.9 crore in Q1FY27. The first half of FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves.

Key Financial Highlights

Gross profit stood at Rs. 93.1 crore, up 26.4% QoQ, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. EBITDA stood at Rs. 41.4 crore, up 67.4% QoQ, with EBITDA margin at 21.1% against 13.7% in Q1FY27. Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% QoQ to Rs. 10.5 crore in Q2FY27.

Strategic Developments

Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 12.4% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock holds at 28% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 126.1% and profits at 111.8% CAGR, with D/E of 0.00. Meanwhile, the stock dips 12.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.